Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering

Lucid Diagnostics Inc.

2025-Q2 EPS reported -$0.52 vs consensus -$0.12 ▼ miss (-321.4%)

Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.
GAAP net loss $7.9M ($0.08 EPS); non-GAAP adjusted loss $9.9M ($0.10 EPS).
Ended Q2 with $31.1M cash after $16.1M public offering; runway extended into 2026.
Medicare contractor advisory committee meeting scheduled September 4 for EsoGuard coverage.
Partnered with Hoag for esophageal precancer testing; joined Russell 2000/3000 indexes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.